kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Human VEGF-C Protein, 50µg  

Recombinant Human VEGF-C Protein, 50µg

Recombinant Human VEGF-C /FLT4L Protein (rhVEGF-C) Thr 103 - Arg 227 was produced in human 293 cells (HEK293), His Tag

Synonyms: VEGFC, Flt4-L, VRP, Vascular endothelial growth factor-related proteinVascular endothelial growth factor CFlt4 ligand

More details


Availability: within 7 days

300,00 €

Vascular endothelial growth factor C is also known as VEGFC, Flt4-L and VRP, it contains the C-terminal propeptide which has an unusual structure with tandemly repeated cysteine-rich motifs. Upon biosynthesis, VEGFC is secreted as a non-covalent momodimer in an anti-parellel fashion. VEGFC is a member of the platelet-derived growth factor/vascular endothelial growth factor (PDGF/VEGF) family, is active in angiogenesis, lymphangiogenesis and endothelial cell growth and survival, and can also affect the permeability of blood vessels. This secreted protein undergoes a complex proteolytic maturation, generating multiple processed forms that bind and activate VEGFR-3 receptors. Only the fully processed form can bind and activate VEGFR-2 receptors. The structure and function of this protein is similar to those of vascular endothelial growth factor D (VEGF-D). VEGFC may function in angiogenesis of the venous and lymphatic vascular systems during embryogenesis, and also in the maintenance of differentiated lymphatic endothelium in adults. Overexpression of VEGF-C causes lymphatics to enlarge possibly facilitates metastasis.

Recombinant Human VEGF-C /FLT4L Protein (rhVEGF-C), His Tag (VEC-H4225) is expressed from human 293 cells (HEK293). It contains AA Thr 103 - Arg 227 (Accession # AAH35212.1).
Predicted N-terminus: Thr 103

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 14.9 kDa. The protein migrates as 19-25 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Less than 1.0 EU per μg of the rhVEGF-C by the LAL method.

>95% as determined by SDS-PAGE.

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally Mannitol or Trehalose are added as protectants before lyophilization. 

See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Avoid repeated freeze-thaw cycles.
No activity loss was observed after storage at:
In lyophilized state for 1 year (4°C-8°C); After reconstitution under sterile conditions for 1 month (4°C-8°C) or 3 months (-20°C to -70°C).

Please refer to product data sheet.


(1) Orpana A, Salven P , 2003, Leuk. Lymphoma 43 (2): 219–24.
(2) Joukov V, et al., 1996, EMBO J., 15(2): 290-98.